Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02396745 · ClinicalTrials.gov registry record · NA
TECR & ECM Placement for Esophageal High Grade Dysplasia
A NA study, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT02396745 is a NA study that was terminated before completion, run by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute). The registered enrollment target is 1 participants.
The verdict
NCT02396745, a NA study, was terminated before completion, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study will test the safety and effectiveness of esophageal transoral endoscopic circumferential resection (TECR) using an extracellular matrix (ECM) placement to treat Barrett's esophagus in patients with high-grade dysplasia (HGD). Endoscopic circumferential resection using ECM placement has been introduced as a less invasive, externally incision-less approach to treat patients with esophageal high grade dysplasia; a pre-cancerous condition. In this procedure, the entire length of diseased (abnormal) mucosa (esophagus lining) will be removed using an endoscope that will be inserted through the mouth. The ECM will be placed over the area that is being removed with a temporary, expandable stent to prevent narrowing of the esophagus. The stent is being used to hold the ECM in place as the body begins the healing process. This stent will be removed 14 days (±4 days) after this procedure. Follow-up esophagogastroduodenoscopies (EGD), barium swallow x-ray tests, and questionnaires will take place for 12 months following the procedure. The result of this study may help doctors determine if this procedure would be a more effective treatment option for HGD in the future.
Interventions
- DEVICE Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-01-25 |
| Est. Completion | 2018-03-22 |
| Phase | NA |
Sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)34 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02396745
The ClinicalTrials.gov registry entry for NCT02396745 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex)) is the first listed.
NCT02396745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02396745 about?
NCT02396745 is a clinical study titled "TECR & ECM Placement for Esophageal High Grade Dysplasia". This study will test the safety and effectiveness of esophageal transoral endoscopic circumferential resection (TECR) using an extracellular matrix (ECM) placement to treat Barrett's esophagus in patients with high-grade dysplasia (HGD). Endoscopic circumferential resection using ECM placement has b...
What is the current status of trial NCT02396745?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2016-01-25. Estimated completion is 2018-03-22.
What interventions are being tested in trial NCT02396745?
The interventions under investigation include: Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex)) (DEVICE).
Who is sponsoring clinical trial NCT02396745?
This trial is sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.